(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
PBM Tools PBM Tools Will Save Health Plan Sponsors and Consumers More than $1 Trillion on Prescription Drug Costs As prescription drug spending continues to increase, research shows PBMs’ cost savings and patient care management tools should reduce prescription drug
Upcoming Events Events 10 Nov 10 Nov – 11 Nov Test 2021-11-10 01:00 AM – 2021-11-11 03:00 AM Online Event PCMA Spring Webinar Series 2020 The live webinar series is designed to highlight drug supply chain executives’ thoughts and strategies
Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing, “The Need to Make Insulin Affordable for All Americans,”
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from the IQVIA Institute that shows net prescription spending is decreasing in settings in which pharmacy benefit management (PBM) tools are widely used.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on today’s remarks by Food and Drug Administration Commissioner Scott Gottlieb, specifically those appearing to reference drug manufacturer abuses of risk evaluation and mitigation strategies (REMS) that
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
©2024 PCMA. All Rights Reserved.
